Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
ctDNA
Description:
In cancer research, ctDNA usually means cell-free DNA released by tumors into body fluids; it can also denote chloroplast DNA.
Related topics:
Cancer Genomics and Diagnostics (17%),
Cancer Immunotherapy and Biomarkers (8%),
Advanced Breast Cancer Therapies (8%),
Lung Cancer Treatments and Mutations (7%)
Wikidata ID:
wiki/Q19596321
OpenAlex ID:
keywords/ctdna
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
2019
·
Wenxiao Jia
, Qianqian Gao
, et al.
·
Cancer Biology and Medicine
·
207
PDF
Evaluation of pre-analytical factors affecting plasma DNA analysis
2018
·
Havell Markus
, Tania Contente-Cuomo
, et al.
·
Scientific Reports
·
171
PDF
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
2022
·
Prokop Vodicka
, Pavel Klener
, et al.
·
OncoTargets and Therapy
·
84
PDF
Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients
2020
·
Paul van der Leest
, Pieter A. Boonstra
, et al.
·
Cancers
·
80
PDF
Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
2023
·
Timothy A. Yap
, David J. Kwiatkowski
, et al.
·
Cancer Research
·
75
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
2023
·
Montreh Tavakkoli
, Stefan K. Barta
·
American Journal of Hematology
·
59
PDF
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
2021
·
Alessandra Raimondi
, Federica Palermo
, et al.
·
Cancers
·
57
PDF
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
2024
·
Doaa Bugazia
, Ebtesam Al-Najjar
, et al.
·
Frontiers in Oncology
·
55
Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine
2016
·
Ana Egatz-Gomez
, Ceming Wang
, et al.
·
Biomicrofluidics
·
52
Biological action of molecular adduct pyrazole:trichloroacetic acid on Candida albicans and ctDNA - A combined experimental, Fukui functions calculation and molecular docking analysis
2019
·
S. Balachandar
, M. Dhandapani
·
Journal of Molecular Structure
·
51
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
2020
·
Erika Paige Hamilton
, Mafalda Oliveira
, et al.
·
Journal of Clinical Oncology
·
42
PDF
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion ( MET Amp/Ex14∆ ).
2020
·
D. Ross Camidge
, Filip Janku
, et al.
·
Journal of Clinical Oncology
·
42
On the interaction of daunomycin with synthetic alternating DNAs: Sequence specificity and polyelectrolyte effects on the intercalation equilibrium
1988
·
Luigi Emilio Xodo
, Giorgio Manzini
, et al.
·
Biopolymers
·
41
Water-soluble Cu(II)-complexes of Schiff base amino acid derivatives as biological reagents and sufficient catalysts for oxidation reactions
2020
·
Ahmad D.M. Mohamad
, Eman R. El-Shrkawy
, et al.
·
Journal of the Taiwan Institute of Chemical Engineers
·
36
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
2024
·
Marco Tagliamento
, Marie Morfouace
, et al.
·
npj Precision Oncology
·
35
PDF
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA)
2021
·
David Krug
, Reinhard Vonthein
, et al.
·
Clinical and Translational Radiation Oncology
·
33
PDF
Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management
2022
·
Sadia Hassan
, Adeeb Shehzad
, et al.
·
Biomedicines
·
32
PDF
Effect of oxy-vanadium (IV) and oxy-zirconium (IV) ions in O,N-bidentate arylhydrazone complexes on their catalytic and biological potentials that supported via computerized usages
2021
·
Mohamed Shaker S. Adam
, Omar M. El-Hady
, et al.
·
Journal of the Taiwan Institute of Chemical Engineers
·
28
Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)
2020
·
Miguel Martín
, Christoph Zielinski
, et al.
·
Cancer Research
·
28
Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy
2018
·
Kerstin Zwirner
, Franz J. Hilke
, et al.
·
Radiotherapy and Oncology
·
27
Capecitabine as a minor groove binder of DNA: molecular docking, molecular dynamics, and multi-spectroscopic studies
2018
·
Shuangshuang Zhang
, Hongqin Yang
, et al.
·
Journal of Biomolecular Structure and Dynamics
·
27
Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)
2020
·
Yan Gao
, Huiqiang Huang
, et al.
·
Blood
·
26
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024
·
Monica Niger
, Federico Nichetti
, et al.
·
BMC Cancer
·
25
PDF
Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
2024
·
Pashtoon Murtaza Kasi
, Mehraneh D. Jafari
, et al.
·
Journal of Clinical Oncology
·
25
PDF
Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
2022
·
Manish Patel
, Carlos Alemany
, et al.
·
Cancer Research
·
25
Show more works
View as search
Works count:
613
Citation count:
2,864
Year
Topic
Type